Beneficial metabolic impact of the novel immunosuppressant rapamycin in chronic canine islet autograft recipients.
Surgical-Medical Research Institute, University of Alberta, Edmonton, Canada.
N M
NM
Kneteman
J R
JR
Lakey
T
T
Wagner
D
D
Finegood
D000818:Animals; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004285:Dogs; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood / Q000378:metabolism; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects / Q000276:immunology / Q000502:physiology*; D011090:Polyenes / Q000009:adverse effects / Q000627:therapeutic use*; D020123:Sirolimus; D013997:Time Factors; D014182:Transplantation, Autologous
D007166:Immunosuppressive Agents; D007328:Insulin; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus